Budget 2026 proposes ₹10,000 crore push to strengthen India’s biopharma sector

In the Union Budget 2026-27, the government announced the launch of Biopharma SHAKTI, short for Strategy for Healthcare Advancement through Knowledge, Technology and Innovation, aimed at positioning India as a global biopharma manufacturing hub.

The programme will be rolled out with an outlay of ₹10,000 crore over the next five years and will focus on building a strong ecosystem for domestic production of biologics and biosimilars, according to information from the PIB.

As part of the initiative, a dedicated biopharma network will be created, including the establishment of three new National Institutes of Pharmaceutical Education and Research and the upgradation of seven existing institutes. The plan also includes setting up a nationwide network of more than 1,000 accredited clinical trial sites across India to support research and innovation.